High-Grade Papillary Urothelial Carcinoma of the Renal Pelvis: A Radiologic Approach to Persistent Gross Hematuria and CT Urography

Executive Clinical Summary

A 63-year-old woman presented with persistent gross hematuria for two months. CT urography demonstrated an infiltrative soft-tissue mass centered in the upper portion of the left kidney and extending toward the mid kidney. The lesion contained multiple small calcifications and was closely associated with the left renal pelvis and upper collecting system. It also extended toward the proximal ureter and produced marked obstruction of the left renal pelvis with impaired contrast passage on delayed excretory imaging.

The final diagnosis was high-grade papillary urothelial carcinoma.

The central radiologic problem in this case is not simply the detection of a renal mass. The more important question is the origin of the tumor. A mass involving the kidney may represent a renal parenchymal neoplasm such as renal cell carcinoma (RCC), or it may represent a urothelial malignancy arising from the renal pelvis or collecting system and secondarily invading the renal parenchyma.

That distinction can substantially influence the diagnostic pathway, staging strategy, surgical planning, and subsequent oncologic management.

In this case, the combination of persistent painless gross hematuria, a renal pelvic-centered infiltrative mass, extension toward the proximal ureter, collecting-system obstruction, and delayed excretory abnormality creates a highly coherent imaging pattern for upper tract urothelial carcinoma (UTUC).

Key Clinical Questions

When a renal mass is encountered in a patient with persistent hematuria, five questions should immediately guide image interpretation:

Is the mass centered in the renal parenchyma or the collecting system?
Does the lesion demonstrate continuity with the renal pelvis or ureter?
Does it produce collecting-system obstruction or impaired urinary drainage?
Could the apparent renal mass actually represent urothelial carcinoma rather than RCC?
What imaging findings suggest locally advanced or high-risk disease?

These questions are more useful than simply labeling the lesion as a “renal mass.”

Introduction: When Hematuria Changes the Diagnostic Direction

Hematuria is common, and many patients with blood in the urine ultimately have benign or nonmalignant causes. However, persistent or recurrent gross hematuria, particularly when painless, requires careful evaluation for urinary tract malignancy.

The clinical scenario in this case is therefore important. The patient had visible hematuria continuing for two months without the presentation being dominated by severe flank pain or another obvious benign explanation. CT urography subsequently revealed a renal mass with a distribution that did not fit comfortably into the classic pattern of a conventional renal parenchymal tumor.

The lesion was centered in the upper portion of the left kidney, extended into the mid kidney, involved the renal pelvis, and continued toward the proximal ureter. Delayed excretory images demonstrated severe obstruction and impaired contrast passage.

This is where radiologic reasoning becomes particularly valuable.

A renal mass should not be interpreted in isolation from the collecting system. The kidney and urinary tract form a continuous anatomic pathway, and urothelial tumors can grow along that pathway. Recognizing this relationship can shift the differential diagnosis from a conventional renal neoplasm toward UTUC.

Learning Objectives

By the end of this article, readers should be able to:

Recognize the imaging pattern of high-grade papillary urothelial carcinoma involving the renal pelvis.
Distinguish a collecting-system-centered tumor from a primarily renal parenchymal mass.
Understand the complementary roles of nephrographic and excretory-phase CT urography.
Identify imaging features that suggest obstruction and locally invasive disease.
Understand why CT imaging alone cannot provide histologic confirmation.
Appreciate how imaging findings contribute to risk assessment and treatment planning.

Anatomy Review: Why the Renal Pelvis Matters

The renal collecting system begins with the minor calyces, which converge into major calyces and then the renal pelvis. The renal pelvis continues inferiorly as the ureter, ultimately transporting urine to the urinary bladder.

The entire collecting system is lined by urothelium. This continuous epithelial surface explains why urothelial carcinoma may occur at multiple locations along the urinary tract.

From a radiologic perspective, the renal pelvis is particularly important because it lies centrally within the kidney and is surrounded by renal sinus structures. A tumor arising from the urothelium can therefore appear to occupy the central kidney while extending into adjacent renal parenchyma.

This produces a potentially misleading appearance.

A mass centered in the renal sinus or collecting system may be mistaken for a renal parenchymal neoplasm if the relationship between the lesion and collecting system is not carefully examined.

For this reason, the renal pelvis, calyces, proximal ureter, renal sinus, and adjacent renal parenchyma should be interpreted together.

Case Presentation

Patient Profile

Age: 63 years
Sex: Female

Presenting Symptom

The patient presented with two months of persistent gross hematuria.

Imaging Examination

CT urography was performed.

Major CT Findings

The examination demonstrated:

An infiltrative soft-tissue mass centered in the upper portion of the left kidney.
Extension toward the mid kidney.
Multiple small calcifications within the mass.
Involvement of the left renal pelvis.
Extension toward the proximal ureter.
Severe obstruction of the left renal pelvis.
Impaired contrast passage on delayed excretory imaging.
Mild dilatation of portions of the lower-pole collecting system.
Layering heterogeneous material within a middle calyx, considered compatible with blood products or proteinaceous material.
The left renal vein remained patent, without definite renal venous invasion described in the case.

Final Diagnosis

High-grade papillary urothelial carcinoma.

The case therefore provides an important example of why a renal mass associated with the collecting system should not automatically be classified as RCC.

Pathophysiology

Urothelial carcinoma arises from malignant transformation of the urothelial lining of the urinary tract. The biologic behavior of the tumor depends on its histologic and molecular characteristics, including tumor grade and stage.

Papillary urothelial tumors grow from the epithelial surface and may project into the collecting system. With more aggressive disease, the tumor can infiltrate beyond the urothelial surface into the renal parenchyma or surrounding tissues.

The term high-grade has particular clinical significance. High-grade urothelial carcinoma is associated with a greater likelihood of invasive and clinically aggressive disease than low-grade tumors.

From a radiologic standpoint, therefore, the task is not merely to identify a filling defect. The radiologist should determine whether there is evidence of:

Renal parenchymal invasion
Renal sinus involvement
Peripelvic extension
Ureteral involvement
Obstruction
Lymphadenopathy
Vascular involvement
Adjacent-organ invasion
Distant metastatic disease

The imaging report should communicate these findings in a way that is useful for staging and treatment planning.

Epidemiology and Risk Factors

Upper tract urothelial carcinoma is relatively uncommon compared with urothelial carcinoma of the bladder, accounting for approximately 5–10% of urothelial carcinomas.

Important recognized risk factors include smoking and certain environmental exposures. Aristolochic acid exposure has been associated with UTUC in particular geographic and epidemiologic settings. Lynch syndrome is also an important hereditary risk factor because defects in DNA mismatch repair pathways can increase susceptibility to upper tract urothelial carcinoma.

The relevance of risk factors should be considered in clinical context rather than used as a substitute for imaging and pathologic evaluation.

A patient does not need to have a classic risk profile for UTUC to occur.

Clinical Presentation

Hematuria Is the Major Warning Sign

Hematuria is the most important presenting symptom of UTUC.

In this case, the key clinical clue was persistent gross hematuria without a dominant pain syndrome.

This matters because malignancy-related urinary bleeding can be intermittent. The disappearance of visible blood does not necessarily indicate that the underlying cause has resolved.

Other symptoms may occur when urinary drainage becomes impaired. Tumor-related obstruction of the renal pelvis or ureter can lead to flank discomfort or upper urinary tract dilatation.

Thus, the clinical combination of:

Gross hematuria + upper urinary tract abnormality + obstruction

should prompt careful evaluation for an obstructing urothelial lesion.

Imaging Features of UTUC

Why CT Urography Is Central

CT urography combines noncontrast, contrast-enhanced, and excretory-phase imaging to evaluate both the renal parenchyma and the urothelial-lined collecting system.

This combination is particularly useful because UTUC is fundamentally a disease of the urinary tract lining, while its locally invasive manifestations may involve renal parenchyma and surrounding structures.

A practical CT urography interpretation should therefore move through the urinary tract rather than stopping at the first renal mass detected.

Figure 1 — Axial CT Urography

Figure 1. Axial CT urography demonstrating an infiltrative mass involving the upper portion of the left kidney.

Figure Legend:
An irregularly and heterogeneously enhancing infiltrative soft-tissue mass is centered in the upper pole region of the left kidney and extends toward the mid kidney. Multiple small calcifications are present within the lesion. The mass is closely associated with the left renal pelvis and upper collecting system.

Radiologist Interpretation:
The lesion demonstrates a collecting-system-centered distribution with an infiltrative appearance and should raise strong suspicion for upper tract urothelial carcinoma.

Clinical Significance:
The relationship between the mass and the renal collecting system is critical for differentiating UTUC from a primary renal parenchymal tumor.

ALT Text:
Axial CT urography showing an infiltrative calcified mass involving the upper left kidney and renal pelvis.

Figure 2 — Coronal CT Urography

Figure 2. Coronal CT urography demonstrating the longitudinal extent of the tumor.

Figure Legend:
Coronal reconstruction demonstrates extension of the left upper renal mass toward the mid kidney, with inferior and medial extension toward the renal pelvis and proximal ureter. The left renal vein is patent, without definite tumor invasion described on the available images.

Radiologist Interpretation:
Coronal reconstruction clarifies the superior-to-inferior extent of the lesion and its spatial relationship with the collecting system and proximal ureter.

Clinical Significance:
Multiplanar imaging helps establish tumor origin and provides a clearer assessment of the local extent relevant to preoperative planning.

ALT Text:
Coronal CT urography showing a left renal mass extending from the upper pole toward the renal pelvis and proximal ureter.

Five CT Findings That Should Not Be Missed

1. A Renal-Pelvis-Centered Soft-Tissue Mass

When a mass is centered around the renal pelvis or renal sinus rather than projecting predominantly from the peripheral renal cortex, urothelial carcinoma should enter the differential diagnosis.

2. Distortion of the Collecting System

A tumor growing along the collecting system can alter the normal architecture of the calyces and renal pelvis.

The pattern of distortion can provide an important clue to tumor origin.

3. Enhancing Soft Tissue

A true enhancing soft-tissue component should be distinguished from blood clot, debris, or other nonenhancing material.

In a patient with hematuria, this distinction is particularly important.

4. Urinary Tract Obstruction

Tumor involvement of the renal pelvis or ureter can obstruct urinary flow and result in collecting-system dilatation.

5. Impaired Contrast Passage

The excretory phase can reveal the functional consequence of obstruction. A narrowed contrast stream through the involved ureter or poor opacification above an obstructing lesion can be more informative than simply describing “hydronephrosis.”

Figure 3 — Delayed Excretory CT, Axial Image

Figure 3. Delayed excretory CT demonstrating severe obstruction of the left renal pelvis.

Figure Legend:
Delayed excretory imaging demonstrates severe obstruction of the left renal pelvis. Only a thin stream of contrast passes through the involved ureteral segment. Portions of the lower-pole calyces are mildly dilated and opacified. Layering heterogeneous material within a middle calyx may represent blood products or proteinaceous material.

Radiologist Interpretation:
The findings indicate significant tumor-related obstruction of the upper urinary tract with impaired drainage.

Clinical Significance:
The location and severity of obstruction may influence symptoms, renal function, and subsequent treatment planning.

ALT Text:
Delayed axial excretory CT showing severe left renal pelvic obstruction with a thin stream of contrast through the involved ureter.

Figure 4 — Delayed Excretory CT, Coronal Image

Figure 4. Coronal delayed excretory CT demonstrating the extent of upper urinary tract obstruction.

Figure Legend:
Coronal excretory imaging more clearly demonstrates obstruction involving the left renal pelvis and upper ureter. The tumor extends from the renal pelvis toward the proximal ureter and limits normal contrast passage. Residual contrast within lower-pole calyces indicates partial drainage.

Radiologist Interpretation:
The pattern is consistent with tumor-related obstruction of the left upper urinary tract.

Clinical Significance:
Coronal excretory imaging helps define the relationship between tumor extent and impaired urinary drainage.

ALT Text:
Coronal delayed excretory CT demonstrating left renal pelvic and proximal ureteral obstruction by urothelial carcinoma.

Blood Clot Is Not the Final Diagnosis

One of the most useful lessons from this case is that blood seen within the collecting system should not automatically be considered the primary diagnosis.

A patient with gross hematuria may develop blood clots within the renal pelvis or calyces. On CT, these can appear as high-attenuation or layering material.

But the more important question is:

Why is the patient bleeding?

If a clot is present together with an enhancing infiltrative mass, abnormal collecting-system architecture, ureteral discontinuity, or obstruction, the clot should be interpreted as a possible consequence of the underlying lesion rather than the explanation for the entire imaging abnormality.

In this case, the presence of a definite mass alongside layering heterogeneous material makes a tumor-related bleeding process substantially more relevant than an isolated blood clot.

Delayed Nephrogram: A Secondary Finding, Not the Central Diagnosis

Delayed nephrogram refers to delayed or reduced renal parenchymal enhancement relative to the contralateral kidney.

It may occur in association with obstructive uropathy and other abnormalities affecting renal perfusion or drainage.

In this case, however, the renal parenchymal enhancement was described as relatively symmetric despite cortical thinning associated with the mass.

Therefore, the absence of a prominent delayed nephrogram should not distract from the major imaging diagnosis.

The dominant pattern remains:

Renal pelvic tumor → proximal ureteral extension → obstruction → impaired urinary drainage.

Radiologic interpretation should prioritize the most diagnostically coherent pattern rather than allowing one secondary sign to dominate the entire assessment.

Differential Diagnosis

Diagnosis	Key Imaging Pattern	Clinical Clue	Differentiating Point
Upper tract urothelial carcinoma	Renal pelvis/collecting-system-centered infiltrative mass with ureteral extension	Hematuria	Collecting-system origin and urinary obstruction
Renal cell carcinoma	Primarily renal parenchymal mass	Hematuria may occur	Usually centered in renal parenchyma rather than urothelium
Renal infection/abscess	Inflammatory renal changes, fluid collection, surrounding inflammation	Fever, inflammatory symptoms	Infection-related clinical and inflammatory findings
Blood clot	Nonenhancing intraluminal material	Hematuria	Does not explain an enhancing infiltrative mass
Direct invasion from adjacent malignancy	Mass crossing tissue planes from an adjacent organ	Known or suspected primary tumor	Direction and center of tumor growth

The Key Differential: UTUC Versus RCC

This is often the most important diagnostic distinction.

RCC typically arises from renal parenchyma and may expand the kidney, distort the renal contour, or replace normal renal tissue.

UTUC, by contrast, arises from the urothelial lining and often demonstrates a close relationship with the renal pelvis, calyces, or ureter.

However, these patterns are not absolute. An advanced urothelial tumor may invade renal parenchyma, while a renal parenchymal tumor may secondarily involve the collecting system.

Therefore, the correct question is not simply:

“Where is the mass?”

It is:

“Where did the mass most likely begin, and in which direction has it grown?”

Multimodal Imaging Comparison

Modality	Major Strength	Main Limitation	Best Clinical Question
CT urography	Evaluates renal parenchyma and urothelium	Radiation and iodinated contrast considerations	Where is the tumor and how does it affect the collecting system?
MR urography	Useful alternative when CT is unsuitable	Generally less established than CT urography for routine UTUC evaluation	Can the upper urinary tract be evaluated when CT is unsuitable?
Ultrasound	Accessible and noninvasive	Limited evaluation of small urothelial lesions	Is there hydronephrosis or a gross renal abnormality?
Cystoscopy	Direct visualization of bladder mucosa	Does not directly evaluate the entire upper tract	Is there synchronous bladder tumor?
Ureteroscopy	Direct visualization and tissue acquisition	Invasive procedure	What does the lesion look like endoscopically and what is its histology?

CT urography and ureteroscopy should therefore be viewed as complementary rather than interchangeable investigations.

Imaging Physics: Why the Excretory Phase Matters

The diagnostic value of CT urography comes from its ability to examine different tissue and functional characteristics at different phases.

The nephrographic phase provides useful information about renal parenchymal enhancement and local tumor extent.

The excretory phase, by contrast, demonstrates contrast-opacified urine within the collecting system and ureters. This makes it particularly valuable for identifying:

Filling defects
Ureteral narrowing
Collecting-system distortion
Obstruction
Impaired drainage
The longitudinal extent of urothelial lesions

In other words, the excretory phase changes the question from:

“Is there a renal mass?”

to:

“What is happening to the urinary tract because of this lesion?”

That distinction is central to interpreting UTUC.

Clinical Diagnostic Workflow

This workflow emphasizes an important principle: imaging establishes anatomy and disease extent, while endoscopic and pathologic assessment provides complementary information.

Can CT Alone Diagnose High-Grade Papillary Urothelial Carcinoma?

No.

CT urography can strongly suggest UTUC and can provide extensive information about tumor location, morphology, obstruction, and local extent. However, CT cannot by itself establish the histologic grade of urothelial carcinoma.

The diagnostic pathway may include urine cytology, cystoscopy, ureteroscopy, and tissue sampling depending on the clinical situation.

Each test answers a different question:

CT urography: Where is the lesion, and how extensive is it?

Cystoscopy: Is there synchronous bladder disease?

Ureteroscopy: What does the lesion look like directly, and can tissue be obtained?

Pathology: What is the histologic diagnosis and tumor grade?

A biopsy is also not necessarily a perfect representation of the entire tumor because sampling may not capture the deepest or most aggressive component.

Risk Stratification: Why “High-Grade” Matters

The word high-grade is not merely a pathology descriptor. It has direct implications for clinical risk assessment.

High-grade UTUC is more strongly associated with invasive and advanced disease than low-grade disease. Consequently, imaging should focus on features that may indicate high-risk behavior.

These include:

Infiltrative growth
Large tumor burden
Collecting-system obstruction
Hydronephrosis
Local tissue invasion
Lymph-node involvement
Distant metastases
Multifocal disease
Poor renal function

Imaging does not replace pathology-based risk stratification, but it contributes essential anatomic information.

Treatment Strategy

Radical Nephroureterectomy

For appropriately selected patients with high-risk, nonmetastatic UTUC, radical nephroureterectomy (RNU) is a major curative surgical strategy.

The operation is not simply removal of the kidney. Oncologic management generally involves removal of the affected kidney and ureter with appropriate management of the distal ureter and bladder cuff.

For a tumor that is centered on the renal pelvis, extends into the proximal ureter, and demonstrates a relatively broad infiltrative distribution, preservation of renal tissue cannot automatically take priority over oncologic control.

The ultimate decision depends on the complete clinical and pathologic risk profile.

Kidney-Sparing Treatment

Kidney-sparing management has an important role in selected patients, particularly those with appropriately selected low-risk localized tumors or special circumstances in which preservation of renal function is particularly important.

The advantage is preservation of functioning renal tissue.

The trade-off is the need for close surveillance because residual or recurrent disease may occur.

The key clinical question is therefore not simply:

“Can the kidney be preserved?”

It is:

“Can the kidney be preserved without compromising oncologic safety?”

Adjuvant Chemotherapy and the POUT Trial

Treatment of high-risk UTUC does not necessarily end with surgery.

The POUT trial provided important evidence supporting adjuvant platinum-based chemotherapy after nephroureterectomy in patients with locally advanced or node-positive, nonmetastatic UTUC.

The case materials report improved disease-free outcomes with gemcitabine-platinum chemotherapy compared with observation in the relevant postoperative population.

The reported long-term results included a 5-year disease-free survival of approximately 62% with chemotherapy versus 45% with observation, while 5-year overall survival was approximately 66% versus 57%.

An important clinical consideration is treatment timing. Renal function can decline after nephroureterectomy, potentially affecting eligibility for cisplatin-based chemotherapy. Consequently, treatment sequencing should be considered as part of the overall oncologic strategy rather than as isolated decisions.

Prognosis

Prognosis in UTUC depends strongly on pathologic stage and tumor grade.

High-grade disease, muscle invasion, lymph-node metastasis, adjacent tissue invasion, distant metastasis, multifocality, larger tumor burden, hydronephrosis, and impaired renal function can all be associated with higher-risk disease.

Imaging therefore has a role beyond detection.

The radiologist should actively assess:

Tumor origin → local extension → obstruction → lymph nodes → distant metastases.

A report that only states “left renal mass” may be technically accurate but clinically incomplete.

Artificial Intelligence Perspective

AI is increasingly being incorporated into medical imaging workflows, but its role in UTUC should be approached realistically.

Potential applications include computer vision for lesion detection, segmentation of the collecting system, identification of suspicious filling defects, image prioritization, and extraction of structured imaging features.

A future multimodal system could potentially integrate:

CT urography
Laboratory information
Urine cytology
Endoscopic findings
Pathology
Previous imaging
Clinical history

to support risk assessment.

However, these applications should not be confused with validated autonomous diagnosis.

The clinically useful role of AI is more likely to be decision support and workflow augmentation than replacement of radiologic judgment.

AI Workflow

An AI system that detects a suspicious renal mass but fails to recognize its continuity with the renal pelvis would not adequately solve the clinical problem.

Enterprise Healthcare Perspective

At hospital scale, AI deployment requires more than a high-performing algorithm.

The workflow must connect imaging acquisition, PACS, AI inference, reporting, and clinical systems.

A conceptual enterprise architecture is:

DICOM → PACS/VNA → AI Orchestration → AI Model → Inference → PACS Visualization → Radiologist → RIS → EMR

Interoperability standards such as DICOM, HL7, and FHIR can support integration across systems.

Governance is equally important. The hospital must be able to determine:

Which AI model analyzed the examination
Which version was used
When inference occurred
Whether the model was available
Whether the radiologist accepted or rejected the AI suggestion
How errors are monitored
Whether model performance changes after deployment

These considerations become particularly important for medical AI used in oncologic imaging.

AI Failure Modes

AI can fail in several clinically meaningful ways.

Failure Mode	Potential Problem	Radiologist Response
False negative	Small or subtle urothelial lesion missed	Review collecting system systematically
False positive	Clot or debris classified as tumor	Confirm enhancement and morphology
Wrong localization	Lesion assigned to renal parenchyma rather than pelvis	Verify origin on multiplanar images
Poor image quality	Reduced model performance	Interpret original images independently
Domain shift	Different scanner/protocol population	Treat output as supportive rather than definitive
Hallucinated explanation	AI-generated rationale may be incorrect	Verify every clinical claim against images
Alert fatigue	Excessive nonactionable alerts	Prioritize clinically meaningful findings

The key principle is simple:

AI confidence is not the same as diagnostic truth.

Future Precision Medicine

The next phase of UTUC imaging may involve integration of imaging phenotype with molecular and pathologic information.

Potential research directions include:

Radiomics
Radiogenomics
Multimodal foundation models
Vision-language models
Federated learning
Digital twins
Synthetic data
Physics-informed AI

These technologies may eventually help characterize tumor biology from imaging.

However, most such applications remain research or developmental concepts rather than routine clinical standards for an individual patient.

The distinction between current clinical practice and future research should remain explicit.

Ten Expert Insights

Expert Insight 1 — The Center of the Mass Matters

When a renal mass is found, determine whether its center is in the renal parenchyma or collecting system before assigning a differential diagnosis.

Expert Insight 2 — Follow the Ureter

A suspicious renal pelvic mass should be traced inferiorly toward the ureter. Continuity can provide a valuable clue to urothelial origin.

Expert Insight 3 — Do Not Stop at the Nephrographic Phase

A renal mass may be obvious on contrast-enhanced imaging, but the excretory phase may reveal the most clinically meaningful consequence: obstruction.

Expert Insight 4 — Hematuria Gives the Imaging Context

The same renal mass has a different diagnostic significance in a patient with persistent painless gross hematuria than in a patient undergoing imaging for an unrelated indication.

Expert Insight 5 — A Clot May Be a Consequence, Not the Diagnosis

Blood products inside the collecting system should prompt the question of why bleeding occurred.

Expert Insight 6 — Coronal Images Are Often Decisive

Multiplanar reformats can clarify the superior-inferior extent of the lesion and its relationship with the renal pelvis and proximal ureter.

Expert Insight 7 — “Renal Mass” Is Often Too Nonspecific

For surgical planning, the report should communicate origin, collecting-system involvement, ureteral extension, obstruction, local invasion, vascular involvement, lymph nodes, and metastases.

Expert Insight 8 — Pathology and Imaging Have Different Jobs

Imaging provides anatomic mapping and staging information; pathology establishes histologic diagnosis and grade.

Expert Insight 9 — High-Grade Disease Changes the Conversation

Once high-grade UTUC is established, the focus shifts from simple lesion detection toward oncologic risk assessment and treatment planning.

Expert Insight 10 — The Best AI Is the AI That Fits the Workflow

A technically impressive algorithm has limited clinical value if it does not integrate reliably with PACS, reporting, and multidisciplinary decision-making.

Clinical Pearls

Persistent gross hematuria deserves a complete evaluation even when it is intermittent.
Painless hematuria should raise concern for urinary tract malignancy.
A renal-pelvis-centered mass should prompt consideration of UTUC.
Determine tumor origin before labeling a renal mass as RCC.
Examine the renal pelvis, calyces, and ureter as one continuous system.
Excretory-phase CT is essential for evaluating urinary drainage.
Contrast enhancement helps distinguish tumor from simple clot or debris.
Coronal reconstructions can clarify tumor continuity with the collecting system.
Obstruction is not merely a secondary imaging finding; it may affect renal function and treatment planning.
CT urography strongly supports diagnosis but does not provide histologic confirmation.
Ureteroscopy can provide direct visualization and tissue sampling when indicated.
High-grade pathology should trigger careful assessment of invasive disease and metastatic spread.
Kidney-sparing treatment is a risk-adapted strategy, not an automatic choice.
Postoperative systemic therapy may be important in selected high-risk patients.
Imaging reports should communicate findings in a form that can be used directly for multidisciplinary treatment planning.

Common Diagnostic Pitfalls

Pitfall 1: Automatically Calling Every Renal Mass RCC

The presence of a renal mass does not establish renal cell carcinoma. The collecting-system relationship must be assessed.

Pitfall 2: Ignoring the Excretory Phase

Stopping the interpretation after contrast-enhanced renal imaging can lead to underrecognition of obstruction and ureteral involvement.

Pitfall 3: Calling Intracollecting-System Material “Blood Clot” and Ending the Evaluation

Blood may be secondary to tumor-related bleeding. The surrounding collecting system and renal parenchyma must be evaluated.

Pitfall 4: Focusing Only on Tumor Size

Tumor size is important, but origin, infiltration, obstruction, nodal disease, and metastases may be more clinically consequential.

Pitfall 5: Overcalling Vascular Invasion

A patent renal vein without definite tumor invasion should not be described as venous involvement.

Pitfall 6: Treating CT as Histologic Proof

CT can strongly suggest UTUC but cannot determine histologic grade with certainty.

Pitfall 7: Assuming MRI Must Be Better Because It Is More Advanced

For routine UTUC evaluation, CT urography remains central. MR urography is particularly useful when CT is unsuitable.

Pitfall 8: Treating AI Output as the Final Diagnosis

AI should support, not replace, independent radiologic interpretation and clinical correlation.

FAQ

What is high-grade papillary urothelial carcinoma?

High-grade papillary urothelial carcinoma is a malignant urothelial tumor with aggressive histologic characteristics. When it arises in the renal pelvis or ureter, it is categorized as upper tract urothelial carcinoma.

What is the most important symptom of UTUC?

Hematuria is the most common and clinically important presenting symptom. Persistent or recurrent painless gross hematuria warrants evaluation for urinary tract malignancy.

What is the key CT finding?

A renal-pelvis or collecting-system-centered soft-tissue mass, particularly when associated with ureteral extension and obstruction, should raise strong suspicion for UTUC.

Can UTUC look like a renal mass?

Yes. An infiltrative tumor arising from the renal pelvis can extend into renal parenchyma and appear to be a renal mass.

How can UTUC be differentiated from RCC?

The center and direction of tumor growth are important. UTUC tends to be centered on the collecting system and may extend along the renal pelvis and ureter, whereas RCC more commonly originates within renal parenchyma.

Why is CT urography important?

It allows evaluation of the renal parenchyma, renal pelvis, calyces, ureters, and excretory function-related findings in a coordinated examination.

Can CT confirm high-grade urothelial carcinoma?

No. CT can strongly suggest the diagnosis and define its extent, but histologic confirmation requires appropriate tissue evaluation.

Is MRI always better than CT?

No. CT urography is generally the preferred imaging approach for routine evaluation of UTUC, while MR urography can be an alternative when CT is unsuitable.

Does every UTUC require kidney removal?

No. Treatment is risk-adapted. Selected low-risk localized tumors and certain special clinical situations may be managed with kidney-sparing approaches.

Why does tumor grade matter?

High-grade disease is associated with a greater likelihood of invasive and advanced disease and therefore plays an important role in treatment planning.

Quiz

Question 1

A 63-year-old woman has persistent painless gross hematuria. CT urography shows an infiltrative left renal mass extending from the upper kidney toward the renal pelvis and proximal ureter, with severe obstruction. What is the most likely diagnosis?

① Renal cell carcinoma
② Renal abscess
③ Upper tract urothelial carcinoma of the renal pelvis
④ Simple renal hematoma
⑤ Renal vascular malformation

Correct Answer: ③

Explanation: The combination of hematuria, collecting-system-centered disease, proximal ureteral extension, and obstruction strongly supports upper tract urothelial carcinoma.

Question 2

Why is the excretory phase of CT urography particularly valuable in this setting?

① It evaluates renal function only
② It demonstrates the urinary collecting system and urinary drainage
③ It completely replaces cystoscopy
④ It provides histologic diagnosis
⑤ It detects every microscopic urothelial lesion

Correct Answer: ②

Explanation: Excretory imaging demonstrates contrast within the collecting system and ureters, helping identify filling defects, obstruction, and impaired contrast passage. Very small or flat lesions may remain difficult to detect, and endoscopic assessment may still be required.

Question 3

Which postoperative strategy has evidence supporting consideration in selected patients with locally advanced or node-positive nonmetastatic UTUC after nephroureterectomy?

① Routine radiation therapy for every patient
② Platinum-based adjuvant chemotherapy
③ Kidney-sparing treatment for every patient
④ Long-term observation regardless of risk
⑤ Cystoscopy alone

Correct Answer: ②

Explanation: The POUT trial demonstrated improved disease-free outcomes with gemcitabine-platinum adjuvant chemotherapy in appropriate patients following nephroureterectomy.

Conclusion

The diagnosis of high-grade papillary urothelial carcinoma of the renal pelvis begins long before pathology is available.

It begins with recognizing the clinical significance of persistent gross hematuria and then asking the correct radiologic question: Where did this tumor originate?

In this case, the imaging pattern is coherent:

Persistent gross hematuria

→ CT urography

→ Infiltrative left renal mass

→ Renal pelvis/collecting-system involvement

→ Extension toward the proximal ureter

→ Severe upper urinary tract obstruction

→ High-grade papillary urothelial carcinoma

The most important imaging lesson is that a renal mass should never be evaluated as an isolated object. Its relationship to the renal pelvis, calyces, ureter, renal sinus, surrounding renal parenchyma, vessels, lymph nodes, and distant organs determines its clinical meaning.

CT urography is particularly valuable because it connects anatomy with urinary tract function. The nephrographic phase helps evaluate renal parenchymal involvement, while the excretory phase reveals the effect of the tumor on the collecting system and urinary drainage.

For the radiologist, the practical sequence is straightforward:

Origin → Extent → Collecting-system involvement → Ureteral continuity → Obstruction → Local invasion → Nodes → Metastases.

That approach is more informative than simply reporting a “renal mass,” and it provides the urologist and oncology team with information that can directly contribute to treatment planning.

Most importantly, persistent painless gross hematuria should not be dismissed simply because the bleeding is intermittent or eventually disappears. The symptom may be the first clinical signal of an upper urinary tract malignancy.

In medical imaging, the goal is not merely to find the abnormality.

The goal is to understand where it started, how it spread, what it is obstructing, and what that information means for the patient’s next clinical decision.

Key Takeaways

Persistent or recurrent gross hematuria requires appropriate evaluation.
Painless gross hematuria is an important warning sign for urinary tract malignancy.
UTUC may mimic a renal parenchymal mass when it invades the kidney.
Tumor origin is one of the most important imaging questions.
Renal-pelvis-centered disease with proximal ureteral continuity favors UTUC.
CT urography is central to evaluating the renal parenchyma and urothelium.
Excretory-phase imaging is critical for assessing filling defects, obstruction, and impaired drainage.
Blood products within the collecting system should not automatically be considered the primary diagnosis.
CT supports diagnosis and staging but does not replace pathologic confirmation.
High-grade UTUC requires careful risk assessment and multidisciplinary management.
Radical nephroureterectomy is an important treatment for appropriately selected high-risk nonmetastatic disease.
Kidney-sparing management may be appropriate in selected lower-risk or special clinical situations.
Adjuvant platinum-based chemotherapy has an evidence base in selected high-risk postoperative patients.
AI can assist detection, workflow, and decision support, but radiologist oversight remains essential.
The most useful imaging report communicates origin, extent, obstruction, invasion, nodes, and metastases.

References

[1] R. F. Browne, C. P. Meehan, J. Colville, R. Power, and W. C. Torreggiani, “Transitional cell carcinoma of the upper urinary tract: Spectrum of imaging findings,” RadioGraphics, vol. 25, no. 6, pp. 1609–1627, 2005. DOI: 10.1148/rg.256045517.

[2] R. A. Leder and N. R. Dunnick, “Transitional cell carcinoma of the pelvicalices and ureter,” American Journal of Roentgenology, vol. 155, no. 4, pp. 713–722, 1990. DOI: 10.2214/ajr.155.4.2119098.

[3] M. Jinzaki, K. Matsumoto, E. Kikuchi, K. Sato, K. Horiguchi, Y. Nishiwaki, and S. G. Silverman, “Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract,” American Journal of Roentgenology, vol. 196, no. 5, pp. 1102–1109, 2011. DOI: 10.2214/AJR.10.5249.

[4] H. Nakai, H. Takahashi, C. V. Wellnitz, M. L. Stanton, N. Takahashi, and A. Kawashima, “Imaging of Upper Tract Urothelial Carcinoma,” RadioGraphics, vol. 44, no. 11, 2024. DOI: 10.1148/rg.240056.

[5] A. J. Zganjar, D. D. Thiel, and T. D. Lyon, “Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma,” Translational Andrology and Urology, vol. 12, no. 9, pp. 1456–1468, 2023. DOI: 10.21037/tau-23-45.

[6] P. Gravestock, D. Cullum, B. Somani, and R. Veeratterapillay, “Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades,” Asian Journal of Urology, vol. 11, no. 2, pp. 242–252, 2024. DOI: 10.1016/j.ajur.2022.08.003.

[7] A. J. Birtle et al., “Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial,” The Lancet, 2020. DOI: 10.1016/S0140-6736(20)30415-3.

[8] A. J. Birtle et al., “Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial,” Journal of Clinical Oncology, vol. 42, no. 13, pp. 1466–1471, 2024. DOI: 10.1200/JCO.23.01659.

[9] C. B. Clark, M. Matheny, and J. D. Raman, “Upper tract urothelial carcinoma: epidemiology, presentation, and high-risk endemic populations,” Current Opinion in Urology, vol. 35, no. 1, pp. 53–57, 2025. DOI: 10.1097/MOU.0000000000001242.

[10] M. Bitaraf, M. Ghafoori Yazdi, and E. Amini, “Upper Tract Urothelial Carcinoma (UTUC) Diagnosis and Risk Stratification: A Comprehensive Review,” Cancers, vol. 15, no. 20, 4987, 2023. DOI: 10.3390/cancers15204987.

[11] M. Masson-Lecomte et al., “European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update,” European Urology, vol. 87, no. 6, pp. 697–716, 2025. DOI: 10.1016/j.eururo.2025.02.023.

Medical Disclaimer

This article is intended for medical education and professional discussion. It does not replace individualized medical diagnosis or treatment. Clinical decisions should be based on the complete clinical history, laboratory data, imaging findings, pathology, current guidelines, and multidisciplinary medical assessment.